Table 2. Clinical features associated with response to intravitreal bevacizumab at postoperative 1 month and at last visit.

	Overall	At 1 month after the first IVB			At the last visit
		CR group (n=10)	NCR group (n=32)	P-value	CR group (n=25)	NCR group (n=17)	P-value
Demography
Age (years)	49.4±11.1	45.4±7.8	50.6±11.7	0.101a	47.5±9.2	52.1 ±13.1	0.298a
Male/female	26/16	7/3	19/13	0.715b	16/9	10/7	0.757c
Symptom duration (months)	6.8±10.5	6.7±7.3	6.8±11.4	0.336a	7.0±8.7	6.4±13.0	0.286a
Spherical equivalent (diopters)	-0.45±1.15	-0.28±1.27	-0.52±1.13	0.950a	-0.38±1.19	-0.52±1.15	0.823a
BCVA at baseline (LogMAR)	0.3±0.3	0.1±0.1	0.4±0.4	0.002a	0.3±0.3	0.4±0.4	0.424a
FA features
Classic/DRPE	27/12	5/5	22/7	0.232b	19/4	8/8	0.041b
From leakage to fovea (μm)	796.6±484.1	886.8±644.2	766.5±429.1	0.747a	752.1±339.4	866.4±660.6	0.936a
ICGA features (presence/absence)
Choroidal hyperpermeability	22/0	5/0	17/0	NA	9/0	13/0	NA
Choroidal filling delay	16/6	5/0	11/6	0.266b	6/3	10/3	0.655b
Punctate hyperfluorescence	17/5	3/2	14/3	0.548b	5/4	12/1	0.116b
SD-OCT features (μm)
SRF GLD	3203.7±1058.8	2587.7±893.2	3396.3±1044.2	0.019a	3232.1±1163.2	3162.1±916.5	0.929a
SRF height	213.4±101.0	168.8±76.0	227.4±104.8	0.090a	214.7±105.7	211.6±96.8	0.888a
SRF volume (mm3)	1.0±0.8	0.7±0.5	1.1±0.8	0.090a	1.0±0.8	1.0±0.8	0.798a
Central macular thickness	429.0±107.1	395.5±73.1	439.4±114.7	0.199a	426.1±102.2	433.2±117.1	0.858a
Subfoveal choroidal thickness	419.6±135.2	492.9±96.9	389.0±138.7	0.036a	433.3±123.9	402.3±150.9	0.405a

Abbreviations: BCVA, best corrected visual acuity; CR, complete resolution of subretinal fluid; DRPE, diffuse retinal pigment epitheliopathy; FA, fluorescein angiography; GLD, greatest linear diameter; ICGA, indocyanine green angiography; LogMAR, logarithm of minimal angle of resolution; NA, not available; NCR, no complete resolution of subretinal fluid; SD-OCT, spectral domain optical coherence tomography; SRF, subretinal fluid.

^aMann–Whitney U-test.

^bFisher's exact test.

^cPearson's χ² test.